ArticleFrontiers in medicine2025
Changes in the malignant female reproductive system tumors disease spectrum at the Beijing obstetrics and gynecology hospital in the past 60 years.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the epidemiological trends in the incidence, age distribution, and pathological types of malignant female reproductive system tumors over the past 60 years at the Beijing Obstetrics and Gynecology Hospital. Methods: The types of diseases and basic clinical information of 18,921 patients with malignant female reproductive system tumors admitted to our hospital between January 1960 and December 2019 were collected. Results: A total of 18,921 patients were diagnosed and treated in the last 60 years. Since the establishment of the Department of Gynecological Oncology at our hospital in 1970, the number of patients with gynecological tumors has doubled, and the number of tumor types has also increased, with the highest incidence of cervical cancer, followed by endometrial cancer, ovarian cancer, and trophoblastic tumors. The three most common tumor types were most prevalent among women aged over 36 years. The average age of patients was 49.43 ± 11.65 years for those with cervical cancer, 53.95 ± 9.45 years for endometrial cancer, and 43.04 ± 13.79 years for ovarian cancer. Over the last 20 years, the age of patients with cervical cancer has been decreasing, and the age of patients with endometrial or ovarian cancers has slowly increased. Squamous cell carcinoma (85.61%-100%) was the most prevalent cervical cancer subtype; while, adenocarcinoma (88%-100%) was the most common endometrial cancer subtype and epithelial carcinoma was the most common ovarian cancer subtype. Conclusion: The establishment of a gynecological oncology subspecialty correlated with improved diagnostic capabilities and a marked increase in the number of cases. The observed epidemiological shifts underscore the need for targeted screening programs, as well as preventive and control policies. Furthermore, the proportion, classification, and age distribution characteristics of malignant tumors in the female reproductive system changed over time. These findings provide a foundation for refining national cancer prevention policies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.